Purchase Option

$ 4400
$ 4000
$ 6000


Report

Overview

Acromegaly is a rare disorder caused excessive production of Growth Hormone (GH) by pituitary gland, due to this tissues and bones in the body grows more rapidly which may leads to abnormal hands and feet. When acromegaly is caused before puberty it is called as Gigantism. Early symptoms of Acromegaly includes swollen hands and feet, sleep apnea, difficulty in sleeping, numbness and weakness in hands, changes in skin etc. Acromegaly can be diagnosed by brain scans and blood tests like IGF test, Glucose Tolerance test. Acromegaly can be treated by surgery, radiation therapy and medications like Somatostatin analogs, GH receptor antagonists and Dopamine agonists.


Report

Space Analysis

In March 2015, Novartis Pharmaceuticals commenced Phase IIIb Multicenter, open-label, single arm study to evaluate the efficacy and safety of Pasireotide in Patients with acromegaly inadequately controlled with first generation somatostatin analogues.

Market

ANALYSIS

MARKET SUMMARY
-
3.67% CAGR
  • Study Period- 2020-2025
  • Base Year- 2019
  • CAGR- 3.67%
  • Largest Market- North America
  • Fastest Growing Market- Asia Pacific

Report

Description

  • Acromegaly Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acromegaly treatment along with targets for various drug candidate.
  • The report provides plethora of information pertaining to trail phases, companies involved in the Acromegaly disease pipeline drugs development.
  • This report studies the dynamics of the Acromegaly Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development.
  • The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others.
  • Moreover, the report on Acromegaly disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Quick Overview
-
  • Projected Rise 2019 - 1.54 to 1.6% CAGR in 2026
  • Base Year - 2019
  • Current CAGR - 1.54%- 3.67%
  • Projected Value in 2021 - To rebound & Expand CAGR of 18.8% reaching US 2.42 Billion in 2023

Key

Features of the Report

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

Detailed


segmentation


Location

GEOGRAPHY

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

 

  • Novartis
  • Italfarmaco
  • Chiasma, Inc.
  • Ipsen
  • Endo Pharmaceuticals
  • Pfizer
  • AmbriliaBiopharma, Inc.

Adjacent Markets